The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver…
The purpose of this study is to determine if Nexavar (sorafenib), the study medication, is effective in preventing cancer recurrence in high risk patients following livertransplantation. The purpose of this study is to determine if sorafenib is a safe and effective treatment option for…
This is a prospective, randomized, multi-center, controlled study for subjects with end stage liver disease who require a livertransplant, comparing whole liver preservation via hypothermic machine perfusion (HMP) using the LLT System…
In this study, we will collect information from the medical record of pediatric livertransplant recipients who received live vaccines as part of their routine post-transplant care. This data will be combined with data from other centers across the United States and…
The purpose of the study is to collect scientific data on pediatric livertransplantation to learn more about how children do after livertransplant. Collecting these data is expected to help researchers learn more about…
The purpose of this study is to determine if the administration of non-absorbable antibiotics (rifaximin) for the first three months after livertransplant period will reduce the amount of fibrosis (scarring of the liver) in liver…
The purpose of this study is to investigate a new therapeutic regimen with or without steroids in the pediatric population. The aim is to find out whether everolimus is safe and has beneficial effects in children who receive a livertransplant. All children will receive a study drug called…
The purpose of this study is to test the safety of different doses of HCIG when given to patients with HCV who receive a livertransplant. It will also provide information about whether HCIG can prevent HCV infection. Participation in the study is expected to last about 10 months. Participants…
The purpose of this study is to see if the study drug Harvoni given for 4 weeks immediately after livertransplantation is safe and able to clear the Hepatitis C virus (HCV) from the body. This study will test a drug named Harvoni for the treatment of chronic genotype 1 or 4 Hepatitis C Virus (…
The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (…
In this study, patients who are listed for a kidney or a livertransplant may be eligible for enrollment, asdetermined by their transplant doctors. The study is looking at patients who do not have hepatitis C virus (HCV) and provide their informed consent to receive…
The purpose of this study is to see if study drugs ABT-450/r/ABT-267, and ABT-333 taken with RBV are safe and able to reduce the amount of Hepatitis C Virus (HCV) in subjects' blood over a 24-week treatment period. These drugs are intended to prevent the HCV from multiplying in the human body. Subjects who participate in this study will be expected to…
The purpose of this research is to study the effects of livertransplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma (HCC). Patients with a diagnosis of HCC and cirrhosis who are listed for a …
The purpose of this study is to determine if eculizumab is safe and could be used to prevent Delayed Graft Function (DGF) following kidney transplantation. DGF is an early complication of kidney transplantation. This condition occurs when the transplanted kidney…
The purpose of this study is to test a new medicine to prevent liver venoocclusive disease (VOD) in patients undergoing hematopoietic stem cell transplant (HSCT) who are at high risk or very high risk for liver VOD following HSCT. Liver…
The purpose of this study is to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during parenchyomous tissue open surgical procedures. Baseline assessments will be performed within 24 hours prior to the scheduled surgery. There will be a physical assessment and a blood draw at the first study visit. Subjects will be randomly…